• Manuel García de Los Ríos, Carlos Wolff, and Erika Duarte.
• Unidad de Diabetes y Nutrición, Departamento de Medicina Occidente, Universidad de Chile, Santiago, Chile.
• Rev Med Chil. 2007 Oct 1; 135 (10): 125312601253-60.

BackgroundBiophasic insulin aspart (InAsBi) is a mixture of 30% of rapid acting soluble aspart insulin and 70% aspart insulin retarded with protamine. The soluble portion reduces postprandial serum glucose rises and the retarded portion reduces basal glucose levels.AimTo assess the efficacy of biphasic insulin aspart in diabetics with a bad metabolic control.Material And MethodsMulticentríc study that included diabetic patients with a glycosilated hemoglobin over 7% that were transferred to treatment with InAsBi, given in one to three daily doses, according to glycemic control and followed for 12 weeks. At the end of follow up, glycosilated hemoglobin levels (HbA1c) were measured again.ResultsOne hundred ninety six patients were enrolled and 154, age 59+/- 12 (84 females), completed the follow up. HbA 1 c levels decreased in at least 1% in 96 and increased in eight cases. In the total group HbA1c decreased from 10.1+/- 1.7 to 8.4+/-1.4% (p <0.01). Those with higher initial values and with oral therapy, had the greatest reductions. At the end of the observation period, 29 patients received one daily dose of InAsBi, 114 two doses and 11 three doses. Two patients had allergy, one systemic and one in the injection site.ConclusionsIn this group of diabetic patients with a bad metabolic control, the use of InAsBi was associated with a significant reduction of glycosilated hemoglobin levels.

19 keywords...

hide…